Details of the Drug

General Information of Drug (ID: DM26E4B)

Drug Name

Moexipril

Synonyms

Moexiprilum; Uniretic; Moexipril (INN); Moexipril [INN:BAN]; Moexiprilum [INN-Latin]; Perdix (TN); Univasc (TN); (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1], [2]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

498.6

Topological Polar Surface Area (xlogp)

1.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The clearance of drug is 441 mL/min [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1 hour [4]
Metabolism: The drug is metabolized via the liver [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.12% [4]
Vd: The volume of distribution (Vd) of drug is 183 L [3]

Chemical Identifiers

Formula: C27H34N2O7
IUPAC Name: (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
Canonical SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC
InChI: InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
InChIKey: UWWDHYUMIORJTA-HSQYWUDLSA-N

Cross-matching ID

PubChem CID: 91270
ChEBI ID: CHEBI:6960
CAS Number: 103775-10-6
DrugBank ID: DB00691
TTD ID: D00HDU
VARIDT ID: DR00006
ACDINA ID: D00443

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin-converting enzyme (ACE)	TTL69WB	ACE_HUMAN	Inhibitor	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 2 (SLC15A2)	DT8QKNP	S15A2_HUMAN	Substrate	[7]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Hypertension

ICD Disease Classification

BA00-BA04

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Angiotensin-converting enzyme (ACE)	DTT	SLC33A1	2.62E-01	-0.01	-0.06
Peptide transporter 1 (SLC15A1)	DTP	PEPT1	6.91E-01	8.30E-03	7.24E-02
Peptide transporter 2 (SLC15A2)	DTP	PEPT2	8.33E-02	-3.63E-02	-1.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Moexipril

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Eprosartan	DM07K2I	Major	Increased risk of hyperkalemia by the combination of Moexipril and Eprosartan.	Hypertension [BA00-BA04]	[31]
Aliskiren	DM1BV7W	Major	Increased risk of hyperkalemia by the combination of Moexipril and Aliskiren.	Hypertension [BA00-BA04]	[32]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Moexipril and TAK-491.	Hypertension [BA00-BA04]	[31]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Moexipril and Indapamide.	Hypertension [BA00-BA04]	[33]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Moexipril and Trichlormethiazide.	Hypertension [BA00-BA04]	[33]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Moexipril and Telmisartan.	Hypertension [BA00-BA04]	[31]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Moexipril and Irbesartan.	Hypertension [BA00-BA04]	[34]
Hydrochlorothiazide	DMUSZHD	Moderate	Additive hypotensive effects by the combination of Moexipril and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[33]
-----------


⏷ Show the Full List of 8 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Moexipril (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Moexipril and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[35]
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Moexipril due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[36]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Moexipril and Repaglinide.	Acute diabete complication [5A2Y]	[37]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Moexipril and Glibenclamide.	Acute diabete complication [5A2Y]	[37]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Moexipril and Tolazamide.	Acute diabete complication [5A2Y]	[37]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Moexipril and Nateglinide.	Acute diabete complication [5A2Y]	[37]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Moexipril and Insulin-aspart.	Acute diabete complication [5A2Y]	[38]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Moexipril and Glipizide.	Acute diabete complication [5A2Y]	[37]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Moexipril and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[39]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Moexipril and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[40]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Moexipril and Cariprazine.	Bipolar disorder [6A60]	[41]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Moexipril and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[42]
Mannitol	DMSCDY9	Moderate	Additive hypotensive effects by the combination of Moexipril and Mannitol.	Bronchiectasis [CA24]	[33]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Moexipril and Olopatadine.	Conjunctiva disorder [9A60]	[43]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Moexipril and Drospirenone.	Contraceptive management [QA21]	[44]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Moexipril and Ardeparin.	Coronary thrombosis [BA43]	[31]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Moexipril and Selegiline.	Depression [6A70-6A7Z]	[45]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Moexipril and Isocarboxazid.	Depression [6A70-6A7Z]	[45]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Moexipril and Tranylcypromine.	Depression [6A70-6A7Z]	[45]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Moexipril and OPC-34712.	Depression [6A70-6A7Z]	[41]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Moexipril and Phenelzine.	Depression [6A70-6A7Z]	[45]
SODIUM CITRATE	DMHPD2Y	Minor	Decreased absorption of Moexipril due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[36]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Moexipril and Cannabidiol.	Epileptic encephalopathy [8A62]	[46]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Moexipril and Phenoxybenzamine.	Essential hypertension [BA00]	[47]
Acetazolamide	DM1AF5U	Moderate	Additive hypotensive effects by the combination of Moexipril and Acetazolamide.	Glaucoma [9C61]	[33]
Methazolamide	DM7J2TA	Moderate	Additive hypotensive effects by the combination of Moexipril and Methazolamide.	Glaucoma [9C61]	[33]
Dichlorphenamide	DMH7IDQ	Moderate	Additive hypotensive effects by the combination of Moexipril and Dichlorphenamide.	Glaucoma [9C61]	[48]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Moexipril and Eplerenone.	Heart failure [BD10-BD1Z]	[49]
Chlorothiazide	DMLHESP	Moderate	Additive hypotensive effects by the combination of Moexipril and Chlorothiazide.	Heart failure [BD10-BD1Z]	[33]
Furosemide	DMMQ8ZG	Moderate	Additive hypotensive effects by the combination of Moexipril and Furosemide.	Heart failure [BD10-BD1Z]	[33]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Moexipril and Bumetanide.	Heart failure [BD10-BD1Z]	[33]
Hydroflumethiazide	DMVPUQI	Moderate	Additive hypotensive effects by the combination of Moexipril and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[33]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Moexipril and Procarbazine.	Hodgkin lymphoma [2B30]	[45]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Moexipril and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[50]
Didanosine	DMI2QPE	Minor	Decreased absorption of Moexipril due to altered gastric pH caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Moexipril and Isosorbide mononitrate.	Hydrocephalus [8D64]	[39]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Moexipril and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[51]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Moexipril and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[52]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Moexipril and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[53]
Potassium chloride	DMMTAJC	Major	Increased risk of hyperkalemia by the combination of Moexipril and Potassium chloride.	Hypo-kalaemia [5C77]	[54]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Moexipril and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[55]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Moexipril and Propiomazine.	Insomnia [7A00-7A0Z]	[41]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Moexipril and ITI-007.	Insomnia [7A00-7A0Z]	[41]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Moexipril and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[56]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Moexipril and Idelalisib.	Mature B-cell leukaemia [2A82]	[57]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Moexipril due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[52]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Moexipril and Ozanimod.	Multiple sclerosis [8A40]	[45]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Moexipril and Promethazine.	Nausea/vomiting [MD90]	[41]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Moexipril and Polythiazide.	Oedema [MG29]	[33]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Moexipril and Safinamide.	Parkinsonism [8A00]	[45]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Moexipril and Rasagiline.	Parkinsonism [8A00]	[45]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Moexipril and Terazosin.	Prostate hyperplasia [GA90]	[47]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Moexipril and Silodosin.	Prostate hyperplasia [GA90]	[47]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Moexipril and Levomepromazine.	Psychotic disorder [6A20-6A25]	[41]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Moexipril and Leflunomide.	Rheumatoid arthritis [FA20]	[52]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Moexipril and Quetiapine.	Schizophrenia [6A20]	[41]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Moexipril and Mesoridazine.	Schizophrenia [6A20]	[41]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Moexipril and Aripiprazole.	Schizophrenia [6A20]	[41]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Moexipril and Iloperidone.	Schizophrenia [6A20]	[41]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Moexipril and Paliperidone.	Schizophrenia [6A20]	[41]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Moexipril and Perphenazine.	Schizophrenia [6A20]	[41]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Moexipril and Molindone.	Schizophrenia [6A20]	[41]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Moexipril and Thiothixene.	Schizophrenia [6A20]	[41]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Moexipril and Trifluoperazine.	Schizophrenia [6A20]	[41]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Moexipril and Risperidone.	Schizophrenia [6A20]	[41]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Moexipril and Amisulpride.	Schizophrenia [6A20]	[41]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Moexipril and Asenapine.	Schizophrenia [6A20]	[41]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Moexipril and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[46]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Moexipril and Naltrexone.	Substance abuse [6C40]	[58]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of hyperkalemia by the combination of Moexipril and Tacrolimus.	Transplant rejection [NE84]	[59]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Moexipril and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[37]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Moexipril and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[37]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Moexipril and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[37]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Moexipril and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[41]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Moexipril and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[60]
-----------


⏷ Show the Full List of 75 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferric oxide black	E00522	16211978	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium carbonate	E00205	11029	Adsorbent; Diluent
Magnesium oxide	E00232	14792	Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Zinc stearate	E00209	11178	lubricant
Haematite red	E00236	14833	Colorant
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Moexipril Hydrochloride 7.5mg tablet	7.5mg	Tablet	Oral
Moexipril 15 mg tablet	15 mg	Oral Tablet	Oral
Moexipril 7.5 mg tablet	7.5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6571).
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
7	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
8	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
9	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
10	Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
11	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
12	The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
13	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
14	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
15	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
16	Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
17	The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
18	Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
19	Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
20	PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
21	Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
22	Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
23	Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
24	Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
25	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
26	Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
27	Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
28	Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
29	Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
30	Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687.
31	Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
32	Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
33	Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
34	Product Information. Micardis (telmisartan). Boehringer-Ingelheim, Ridgefield, CT.
35	Cerner Multum, Inc. "Australian Product Information.".
36	Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
37	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
38	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
39	Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
40	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
41	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
42	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
43	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
44	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
45	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
46	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
47	Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
48	Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
49	Product Information. Inspra (eplerenone). Searle, Chicago, IL.
50	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
51	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
52	Canadian Pharmacists Association.
53	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
54	Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
55	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
56	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
57	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
58	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
59	Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
60	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.